20:40 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
21:23 , Jun 11, 2018 |  BC Extra  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
16:10 , May 4, 2018 |  BC Week In Review  |  Clinical News

Allergan reports mixed data for acute migraine candidate in second Phase III

Allergan plc (NYSE:AGN) said the 50 mg dose of ubrogepant (MK-1602) met the co-primary endpoints in the double-blind, U.S. Phase III ACHIEVE II trial for the acute treatment of migraine. However, the 25 mg dose...
21:09 , Apr 27, 2018 |  BC Extra  |  Clinical News

Allergan reports mixed Phase III data for acute migraine candidate

Allergan plc (NYSE:AGN) said the 50 mg dose of ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE II trial for the acute treatment of migraine. However, the 25 mg dose of the...
16:13 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Allergan's ubrogepant meets in Phase III for acute migraine

Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE I trial for the acute treatment of migraine. The company expects data this half from the Phase III ACHIEVE II...
00:34 , Feb 7, 2018 |  BC Extra  |  Clinical News

Allergan's ubrogepant meets in Phase III for acute migraine

Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE I trial for the acute treatment of migraine. The company expects data this half from the Phase III ACHIEVE II...
07:00 , Sep 19, 2016 |  BioCentury  |  Product Development

Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can...
07:00 , Aug 17, 2015 |  BioCentury  |  Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Merck, Allergan deal

Merck granted Allergan exclusive, worldwide rights to develop and commercialize MK-1602 and MK-8031 -- both oral calcitonin gene-related peptide (CGRP) receptor antagonists for migraines. Next year, Allergan plans to advance MK-8031 and MK-1602 into Phase...
00:49 , Jul 8, 2015 |  BC Extra  |  Company News

Allergan licenses migraine candidates from Merck

Allergan plc (NYSE:AGN) obtained an exclusive, worldwide license to migraine candidates MK-1602 and MK-8031 from Merck & Co. Inc. (NYSE:MRK) for $250 million up front. Both compounds are oral calcitonin gene-related peptide ( CGRP) receptor...